Sortilin Antagonists Block Apoptotic Complexes in Inner Ear Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing loss, such as hearing aids and cochlear implants, primarily address symptoms rather than the underlying causes and are ineffective in preventing or reversing hearing loss, with no approved drugs available for treating the condition.
Innovation Solution
Development of sortilin antagonists, specifically compounds of Formula (I), (II), and (IV), which interfere with the binding of sortilin to pro-neurotrophins, preventing the formation of apoptotic complexes that lead to cell death in inner ear cells, thereby protecting hearing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hearing aids or cochlear implants are used, then hearing symptoms are improved, but the underlying disease pathology is not treated and hair cell damage cannot be prevented or reversed
Solution Approach 1:
The patent converts the harmful apoptotic complex formation into a beneficial protective effect by using sortilin antagonists to block the interaction between sortilin and pro-neurotrophins. This prevents the formation of apoptotic complexes, thereby protecting hair cells from death while maintaining or improving hearing function.
Solution Approach 2:
The patent introduces sortilin antagonists as intermediary substances that mediate between the harmful apoptotic pathway and the protective outcome. These antagonists bind to sortilin and prevent it from forming apoptotic complexes with pro-neurotrophins, thereby intervening in the disease process to protect hair cells.
2Adaptability or versatility
If sortilin binds to pro-neurotrophins, then cellular sorting and signaling functions are performed, but apoptotic complexes form leading to inner ear cell death
Solution Approach 1:
The patent applies local quality by using sortilin antagonists that specifically target and block the harmful apoptotic complex formation while allowing other beneficial sortilin functions to continue. The antagonist selectively interferes with the sortilin-pro-neurotrophin interaction that leads to apoptosis, preserving other cellular sorting and signaling functions.
3Ease of operation
If no pharmacological treatment is available, then current symptomatic treatments can be used, but prevention and restoration of hearing loss cannot be achieved
Solution Approach 1:
The patent implements preliminary action by developing sortilin antagonists that can prevent hearing loss before it occurs or before it progresses. By blocking the apoptotic pathway early, the treatment can prevent hair cell death and potentially restore hearing function, rather than merely managing symptoms after damage has occurred.
Data Source
AI summary
The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I), (II), (III), and (IV), in the treatment or prevention of hearing loss. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of hearing loss in a subject in need thereof.